San Francisco startup Framework Therapeutics can also be focusing on an oral, the moment-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June each time a mid-stage review confirmed typical weight loss of all-around 6% and it designs to get started on Yet another mid-stage demo towards the top of the yr—t